SI20852B - Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj - Google Patents
Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj Download PDFInfo
- Publication number
- SI20852B SI20852B SI200020042A SI200020042A SI20852B SI 20852 B SI20852 B SI 20852B SI 200020042 A SI200020042 A SI 200020042A SI 200020042 A SI200020042 A SI 200020042A SI 20852 B SI20852 B SI 20852B
- Authority
- SI
- Slovenia
- Prior art keywords
- prevention
- treatment
- mesoprogestins
- disorders
- progesterone receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Pričujoči izum opisuje uporabo mezoprogestinov, novega razreda modulatorjev receptorja progesterona (PRM) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj: a) za zdravljenje ginekoloških motenj, kot so endometrioza, maternični fibroidi, postoperativne peritonealne adhezije, disfunkcijska krvavitev (metroragija, menoragija) in dismenoreja; b) za preprečevanje ginekoloških motenj, kot so postoperativne, peritonealne adhezije, disfunkcijska krvavitev maternice (metroragija,menoragija) in dismenoreja; in c) postopek zdravljenja in preprečevanja zgoraj omenjenih motenj pri samici, prednostno ženski, ki potrebuje zdravljenje in preprečevanje ene ali več teh motenj z učinkovito količino mezoprogestina. Mezoprogestini so definirani kot spojine, ki imajo tako agonistične kot antagonistične aktivnosti na receptorju progesterona (PR) in vivo. Stabilizirajo funkcijo PR na intermediatni stopnji agonista in antagonista. Ustreznih funkcijskih stanj ne moremo doseči s progestini aliantiprogestini. Dnevni odmerek mezoprogestina je 0,5 do 100 mg, prednostno 5,0 do 50 mg in najbolj prednostno 10 do 25 mg. J867, J912, J956 in J1042 so prednostni mezoprogestini v smislu izuma.
Claims (3)
1/1 Sl 20852 Mezoprogestini za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj Patentni zahtevki 1. Uporaba učinkovite količine mezoprogestina, izbranega iz skupine, ki jo sestavljajo J867, J912 in J956 za izdelavo zdravila za zdravljenje endometrioze, uterinih fibroidov, disfunkcijske krvavitve maternice (metroragija, menoragija) in dismenoreje, pri čemer je dnevni odmerek mezoprogestina 5,0 do 50 mg.
2. Uporaba učinkovite količine mezoprogestina, izbranega iz skupine, ki jo sestavljajo J867, J912 in J956 za izdelavo zdravila za preprečevanje disfunkcijske krvavitve maternice (metroragija, menoragija) in dismenoreje, pri čemer je dnevni odmerek mezoprogestina 5,0 do 50 mg.
3. Uporaba po zahtevku 1 ali 2, kjer je dnevni odmerek mezoprogestina 10 do 25 mg.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38614199A | 1999-08-31 | 1999-08-31 | |
PCT/US2000/023770 WO2001015679A2 (en) | 1999-08-31 | 2000-08-31 | Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
SI20852A SI20852A (sl) | 2002-10-31 |
SI20852B true SI20852B (sl) | 2009-06-30 |
Family
ID=23524338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200020042A SI20852B (sl) | 1999-08-31 | 2000-08-31 | Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj |
Country Status (34)
Country | Link |
---|---|
EP (1) | EP1229906B1 (sl) |
JP (1) | JP2003535029A (sl) |
KR (3) | KR100755109B1 (sl) |
AR (1) | AR025457A1 (sl) |
AT (1) | ATE375160T1 (sl) |
AU (1) | AU781840B2 (sl) |
BG (1) | BG65817B1 (sl) |
BR (1) | BR0014161A (sl) |
CA (1) | CA2382580C (sl) |
CO (1) | CO5200772A1 (sl) |
CZ (1) | CZ2002704A3 (sl) |
DE (1) | DE60036723T2 (sl) |
DK (1) | DK1229906T3 (sl) |
EA (1) | EA007854B1 (sl) |
EE (1) | EE05172B1 (sl) |
ES (1) | ES2295050T3 (sl) |
HR (1) | HRP20020267A2 (sl) |
HU (1) | HUP0202429A3 (sl) |
IL (1) | IL148416A0 (sl) |
LT (1) | LT5034B (sl) |
LV (1) | LV12941B (sl) |
ME (1) | MEP13808A (sl) |
MX (1) | MXPA02002191A (sl) |
NO (1) | NO20020999L (sl) |
NZ (1) | NZ517471A (sl) |
PE (1) | PE20010578A1 (sl) |
PL (1) | PL198790B1 (sl) |
PT (1) | PT1229906E (sl) |
RO (1) | RO122179B1 (sl) |
RS (1) | RS50283B (sl) |
SI (1) | SI20852B (sl) |
SK (1) | SK287192B6 (sl) |
UA (1) | UA78184C2 (sl) |
WO (1) | WO2001015679A2 (sl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
DE50304970D1 (de) * | 2002-08-02 | 2006-10-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie |
US20040097591A1 (en) * | 2002-11-18 | 2004-05-20 | Kristof Chwalisz | Use of selective progesterone receptor modulators for the treatment of androgen deficiency |
DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
WO2010147184A1 (ja) * | 2009-06-17 | 2010-12-23 | 国立大学法人熊本大学 | 月経困難症の予防及び/又は治療薬 |
US8399432B2 (en) * | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
JP2022548314A (ja) * | 2019-09-23 | 2022-11-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3633244A1 (de) | 1986-09-26 | 1988-03-31 | Schering Ag | Antigestagene zur hemmung der uterinen prostaglandinsynthese |
DE4332284C2 (de) | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE4332283A1 (de) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
US5576310A (en) * | 1994-09-20 | 1996-11-19 | Jenapharm Gmbh | 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds |
US5688810A (en) * | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
EP1382597A3 (en) * | 1994-12-22 | 2004-04-07 | Ligand Pharmaceuticals, Inc. | Steroid receptor modulator compounds and methods |
ES2196063T3 (es) | 1995-02-02 | 2003-12-16 | Schering Ag | Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales. |
DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
AU710139B2 (en) * | 1996-05-01 | 1999-09-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | 21-substituted progesterone derivatives as new antiprogestational agents |
WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
DE19809845A1 (de) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
HUP0105134A2 (hu) * | 1999-01-14 | 2002-04-29 | Bayer Corporation | Szubsztituált 2-arilimino-heterociklusok és ilyen vegyületeket tartalmazó készítmények progeszteron receptorhoz kötődő szerekként való alkalmazásra |
WO2000066590A2 (en) * | 1999-05-04 | 2000-11-09 | Ligand Pharmaceuticals, Inc. | Tetracyclic progesterone receptor modulator compounds and methods |
-
2000
- 2000-08-31 RO ROA200200229A patent/RO122179B1/ro unknown
- 2000-08-31 NZ NZ517471A patent/NZ517471A/en unknown
- 2000-08-31 KR KR1020027002790A patent/KR100755109B1/ko not_active IP Right Cessation
- 2000-08-31 BR BR0014161-5A patent/BR0014161A/pt not_active Application Discontinuation
- 2000-08-31 JP JP2001519893A patent/JP2003535029A/ja active Pending
- 2000-08-31 EE EEP200200104A patent/EE05172B1/xx not_active IP Right Cessation
- 2000-08-31 PE PE2000000893A patent/PE20010578A1/es not_active Application Discontinuation
- 2000-08-31 AU AU69466/00A patent/AU781840B2/en not_active Ceased
- 2000-08-31 PT PT00957914T patent/PT1229906E/pt unknown
- 2000-08-31 DE DE60036723T patent/DE60036723T2/de not_active Expired - Lifetime
- 2000-08-31 CZ CZ2002704A patent/CZ2002704A3/cs unknown
- 2000-08-31 CO CO00065515A patent/CO5200772A1/es not_active Application Discontinuation
- 2000-08-31 ES ES00957914T patent/ES2295050T3/es not_active Expired - Lifetime
- 2000-08-31 SK SK299-2002A patent/SK287192B6/sk unknown
- 2000-08-31 EA EA200200282A patent/EA007854B1/ru not_active IP Right Cessation
- 2000-08-31 DK DK00957914T patent/DK1229906T3/da active
- 2000-08-31 CA CA002382580A patent/CA2382580C/en not_active Expired - Lifetime
- 2000-08-31 KR KR1020087016247A patent/KR20080066095A/ko not_active Application Discontinuation
- 2000-08-31 RS YUP-140/02A patent/RS50283B/sr unknown
- 2000-08-31 HU HU0202429A patent/HUP0202429A3/hu unknown
- 2000-08-31 PL PL353930A patent/PL198790B1/pl not_active IP Right Cessation
- 2000-08-31 EP EP00957914A patent/EP1229906B1/en not_active Expired - Lifetime
- 2000-08-31 UA UA2002032430A patent/UA78184C2/uk unknown
- 2000-08-31 WO PCT/US2000/023770 patent/WO2001015679A2/en active IP Right Grant
- 2000-08-31 AR ARP000104538A patent/AR025457A1/es unknown
- 2000-08-31 KR KR1020077011455A patent/KR100864547B1/ko not_active IP Right Cessation
- 2000-08-31 SI SI200020042A patent/SI20852B/sl not_active IP Right Cessation
- 2000-08-31 AT AT00957914T patent/ATE375160T1/de not_active IP Right Cessation
- 2000-08-31 IL IL14841600A patent/IL148416A0/xx unknown
- 2000-08-31 ME MEP-138/08A patent/MEP13808A/xx unknown
-
2002
- 2002-02-26 BG BG106442A patent/BG65817B1/bg unknown
- 2002-02-28 NO NO20020999A patent/NO20020999L/no not_active Application Discontinuation
- 2002-02-28 MX MXPA02002191A patent/MXPA02002191A/es active IP Right Grant
- 2002-03-21 LT LT2002031A patent/LT5034B/lt not_active IP Right Cessation
- 2002-03-28 HR HR20020267A patent/HRP20020267A2/xx not_active Application Discontinuation
- 2002-03-28 LV LVP-02-53A patent/LV12941B/lv unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU703064B2 (en) | Means and method for hormonal contraception and/or acne treatment | |
UA37259C2 (uk) | Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч | |
PT792152E (pt) | Metodos de contracepcao | |
AR011480A1 (es) | ACIL-ANILIDAS SUSTITUIDAS CON RADICALES (HETERO) CICLICOS, NO ESTEROIDALES, CON ACTIVIDAD GESTÁGENA Y ANDRoGENA MIXTA. | |
BR9813262A (pt) | Terapia de progestina com sangramento controlado | |
WO2004000801A3 (en) | Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions | |
WO2004103159A3 (en) | Methods for modulating endometrium | |
CA2420348A1 (en) | Non-hormonal vaginal contraceptive | |
SI20852B (sl) | Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj | |
BR0013009A (pt) | Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos | |
EP1079790A4 (en) | BROAD SPECTRUM MICROBICIDE AND GERMICIDE COMPOSITIONS, DEVICES AND METHODS | |
AU2284001A (en) | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | |
IL126235A (en) | Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use | |
EA200702604A1 (ru) | Производные бензофуранона как нестероидные модуляторы рецептора прогестерона | |
BG102682A (en) | System for the release of contraceptives having bactericidal and/or antiviral effect | |
YU13902A (sh) | Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene | |
WO2018114514A1 (de) | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind | |
CL2003001544A1 (es) | Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l | |
HRP20020238A2 (en) | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use | |
EA200200285A1 (ru) | Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента композиций для заместительной гормональной терапии (згт) | |
WO2006042561A2 (en) | Intrauterine contraceptive system with copper and progesterone | |
WO2003035059A3 (en) | Spermicides | |
AR028470A1 (es) | Ariltiofeno agonistas de vasopresina, el uso de los mismos para manufactura de un medicamento y composicion farmaceutica | |
WO2003099322A3 (en) | Il-11 derivatives and therapeutic uses thereof | |
Robb-Nicholson | By the way, doctor. My doctor prescribed a low-dose vaginal estrogen cream, applied twice a week, for atrophic vaginitis. I've heard this dose is so low that it carries no health risk. Do you agree? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SP73 | Change of data on owner |
Owner name: SCHERING AKTIENGESELLSCHAFT; DE Effective date: 20041118 |
|
IF | Valid on the event date | ||
OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20090422 |
|
SP73 | Change of data on owner |
Owner name: BAYER SCHERING PHARMA AG; DE Effective date: 20090325 |
|
KO00 | Lapse of patent |
Effective date: 20110413 |